HOUSE COMMITTEE AMENDMENTS

2019 Regular Session

Amendments proposed by House Committee on Insurance to Original House Bill No. 370 by Representative Stokes

1 <u>AMENDMENT NO. 1</u>

2 On page 1, line 2, change "R.S. 22:1053(E)" to "R.S. 22:1053(E), (F), and (G)"

3 AMENDMENT NO. 2

4 On page 1, at the end of line 4, insert "provide for an exception; to require notification of 5 prescriptions for associated conditions; to"

6 AMENDMENT NO. 3

On page 1, at the beginning of line 8, change "22:1053(E) is" to "22:1053(E), (F), and (G)
are hereby"

9 AMENDMENT NO. 4

10 On page 1, line 11, after "Subsection" change " \underline{E} " to " \underline{G} "

11 AMENDMENT NO. 5

12 On page 1, line 19, after "<u>conditions if</u>"delete the remainder of the page and on page 2, 13 delete lines 1 through 3 in their entirety and insert in lieu thereof the following:

| 14 | "at least one of the following criteria is mate |
|----|--|
| | "at least one of the following criteria is met: |
| 15 | (1) The prescribed drug or drug regimen has the United |
| 16 | States Food and Drug Administration approved indication. |
| 17 | (2) The prescribed drug or drug regimen has the National |
| 18 | Comprehensive Cancer Network Drugs and Biologics Compendium |
| 19 | indication. |
| 20 | (3) The prescribed drug or drug regimen is supported by |
| 21 | peer-reviewed, evidenced-based medical literature. |
| 22 | E. The provisions of Subsection D of this Section shall not |
| 23 | apply if the health coverage plan's preferred drug or drug regimen is |
| 24 | considered an equivalent option for therapy or a higher ranked |
| 25 | evidence-based option for therapy as compared to the prescribed drug |
| 26 | or drug regimen according to the National Comprehensive Cancer |
| 27 | Network Guidelines Categories of Evidence and Consensus or the |
| 28 | Categories of Preference. |
| 29 | F. For drugs prescribed for associated conditions as defined |
| 30 | in this Section, the treating healthcare provider shall inform the |
| 31 | health coverage plan that the condition is a condition associated with |
| 32 | stage-four advanced, metastatic cancer when requesting |
| 33 | authorization." |
| | |

34 AMENDMENT NO. 6

- 35 On page 2, at the beginning of line 4, change " $\underline{E.(1)}$ " to " $\underline{G.(1)}$ "
- 36 AMENDMENT NO. 7
- 37 On page 2, between lines 11 and 12, insert the following:

- "(3) As used in this Section, "associated conditions" means the symptoms or side effects associated with stage-four advanced, metastatic cancer or its treatment." 1
- 2